Leigh Baldwin & CO. LLC Takes Position in Amgen Inc. (NASDAQ:AMGN)

Leigh Baldwin & CO. LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 1,250 shares of the medical research company's stock, valued at approximately $326,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Centricity Wealth Management LLC acquired a new stake in shares of Amgen during the 4th quarter worth about $25,000. Pinney & Scofield Inc. acquired a new stake in shares of Amgen in the fourth quarter valued at $26,000. Ritter Daniher Financial Advisory LLC DE lifted its position in Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after buying an additional 51 shares in the last quarter. Synergy Investment Management LLC bought a new position in shares of Amgen in the fourth quarter worth about $34,000. Finally, Atala Financial Inc acquired a new position in shares of Amgen during the fourth quarter worth approximately $34,000. Institutional investors own 76.50% of the company's stock.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several research reports. Bank of America upped their price target on Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research note on Wednesday, March 5th. UBS Group reissued a "neutral" rating and issued a $315.00 price objective (down previously from $319.00) on shares of Amgen in a report on Friday, May 2nd. Piper Sandler cut their price target on Amgen from $329.00 to $328.00 and set an "overweight" rating for the company in a research note on Friday, May 16th. Mizuho raised their price target on Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research report on Wednesday, May 7th. Finally, Johnson Rice set a $294.00 price target on shares of Amgen in a report on Wednesday, March 5th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $309.22.

Amgen Price Performance

NASDAQ:AMGN traded up $3.72 during mid-day trading on Friday, reaching $287.26. The stock had a trading volume of 1,570,907 shares, compared to its average volume of 2,797,973. The stock has a market capitalization of $154.46 billion, a P/E ratio of 38.05, a P/E/G ratio of 2.63 and a beta of 0.51. The firm has a 50 day moving average price of $283.86 and a two-hundred day moving average price of $285.50. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. The company had revenue of $8.15 billion for the quarter, compared to analysts' expectations of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The firm's revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the company earned $3.96 EPS. As a group, analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date is Friday, May 16th. Amgen's payout ratio is 86.86%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.